R&D Navigating geopolitical risks: Practical and legal mitigatio... Geopolitical risk is now front of mind for many pharmaceutical leaders.
R&D Sponsored Inside the NCVR evolution in the UK For years, the UK's clinical research landscape held a frustrating truth: costing and contracting for commercial research needed to evolve if the nation was to remain an attractive option f
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.